Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice

被引：52

作者：

Jiang, Hongchi ^{[1
]}

Tao, Weiyang ^{[1
]}

Zhang, Mu ^{[1
]}

Pan, Shangha ^{[1
]}

Kanwar, Jagat R. ^{[3
]}

Sun, Xueying ^{[1
,2
]}

机构：

[1] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hepatosplen Surg Ctr, Harbin 150001, Heilongjiang, Peoples R China

[2] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand

[3] Deakin Univ, Inst Biotechnol, Inst Technol Res & Innovat, Geelong, Vic 3217, Australia

来源：

CANCER INVESTIGATION | 2010年 / 28卷 / 01期

关键词：

Breast cancer; Paclitaxel; Metastasis; Low-dose metronomic chemotherapy; Maximum tolerable dose; Angiogenesis; Lymphangiogenesis; Vascular endothelial growth factor; Thrombospondin-1; CANCER; CYCLOPHOSPHAMIDE; THROMBOSPONDIN-1; COMBINATION; BIOAVAILABILITY; CAPECITABINE; TRASTUZUMAB;

D O I：

10.3109/07357900902744510

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study investigated the use of low-dose metronomic (LDM) chemotherapy with paclitaxel in a highly metastatic mouse model of 4T1 breast cancers, and compared it with the maximum tolerable dose (MTD) therapy. LDM therapy displayed a stronger anti-tumor activity in suppressing primary and metastatic breast tumors with less degree of side effects, and stronger anti-angiogenic and anti-lymphangiogenic activities than MTD therapy. But MTD therapy showed stronger pro-apoptotic and anti-proliferative activities in situ. Paclitaxel therapy downregulated expression of vascular endothelial growth factor receptor-2 (VEGFR2) and up-regulated expression of thrombospondin-1. The results support the application of paclitaxel LDM therapy to treat advanced breast cancer.

引用

页码：74 / 84

页数：11

共 43 条

[1] PACLITAXEL (TAXOL) IN BREAST-CANCER [J].